Proximagen Limited

Benevolentai Cambridge Limited

Benevolental Cambridge Limited

Proximagen Group Limited

Edward Savory

Iain Simpson

Lee Patient

Michael Higginbottom

David Evans

Kathryn Oliver

Max Espensen

Viet-Anh Anne Horgan

Alison Stewart

Allison Carley

Andrew Graham Cole

Giles Brown

Marianne Nilsson

Tobias Koolmeister

Martin Haraldsson

Rikard Emond

Erik Nordling

Mike Ashwood

Olof Haglund

Sofia Henriksson

Michael Ashwood

Martyn Pritchard

Anne Viet-Anh Horgan

A compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof and the use of the same in therapy: wherein Z, Y, R, W, V, and Rare as defined in claim. 

Imidazo[4,5-C]pyridine derived SSAO inhibitors

Compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof, that are inhibitors of SSAO activity: where V, W, X, Y, Z, R, and Rare as defined herein.

Substituted imidazo[4,5-c]pyridine compounds and compositions thereof

The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.

Compounds I

The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R, X, Y and Rare as defined in the claims.

CXCR4 receptor antagonists

The invention relates to an improved process for the synthesis of (3S, 4S)-tetrahydrofuran-3-yl 4-isopropyl-6,7-dihydro-3H-imidazo[4,5-c]pyridine-5(4H)-carboxylate, and pharmaceutically acceptable salts thereof, such as the methanesulphonic acid salt.

Process for the preparation of (3S,4S)-tetrahydrofuran-3-yl 4-isopropyl-6,7-dihydro-3H-imidazo[4,5-C]pyridine-5(4H)-carboxylate

A process for the preparation of a compound of formula (Ia) or a pharmaceutically acceptable salt, or N-oxide thereof that includes reacting a compound of formula (IIIa) or (Va) with a compound of formula (IX) to form the compound of formula (Ia) 

Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors

The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, Rand Rare as defined in the claims.

The present invention relates to compounds which are inhibitors of SSAO activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumor growth.

Compounds

Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors

A specific crystalline mesylate salt form of (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate, and the use of the same in medicine. (Formula (I)). 

Crystalline compound as semicarbazide-sensitive amine oxidase (SSAO) enzyme inhibitor

The mesylate and sulphate salts of (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate mesylate, and hydrates thereof, and their use in medicine.

Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (SSAO)

Specific compounds of formula (Ia): and pharmaceutically acceptable salts thereof. Pharmaceutical compositions of the specific compounds of formula (Ia) and pharmaceutically acceptable salts thereof. A method for inhibiting tumor growth in a subject that includes administering to the subject an effective amount of a compound selected from the specific compounds of formula (Ia) and pharmaceutically acceptable salts thereof. A method for modulating semicarbazide-sensitive amine oxidase activity in a subject that includes administering to the subject an effective amount of a compound selected from the specific compounds of formula (Ia) and pharmaceutically acceptable salts thereof.

Growing community of inventors

Cambourne, United Kingdom

Edward Savory